skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.06d (Release date: 2017-06-26)
SearchBox Top
SearchBox Bottom
Serdemetan (Code C77904)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Serdemetan

Definition: An orally bioavailable HDM2 antagonist with potential antineoplastic activity.Serdemetan inhibits the binding of the HDM2 protein to the transcriptional activation domain of the tumor suppressor protein p53. By preventing this HDM2-p53 interaction, the proteosome-mediated enzymatic degradation of p53 is inhibited, which may result in the restoration of p53 signaling and thus the p53-mediated induction of tumor cell apoptosis. HDM2 (human homolog of double minute 2), a zinc finger protein, is a negative regulator of the p53 pathway; often overexpressed in cancer cells, it has been implicated in cancer cell proliferation and survival.

Label: Serdemetan

NCI Thesaurus Code: C77904 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C2703092  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
JNJ 26854165

External Source Codes: 
CAS Registry Number 881202-45-5 (see NLM ChemIDplus info)
PDQ Closed Trial Search ID 596734
PDQ Open Trial Search ID 596734 (check for NCI PDQ open clinical trial info)
UMLS CUI C2703092

Other Properties:
     Name Value (qualifiers indented underneath)
code C77904
Contributing_Source FDA
Legacy_Concept_Name HDM2_Inhibitor_JNJ-26854165
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom